Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels.
D000273:Adipose Tissue / Q000378:metabolism; D000818:Animals; D053304:Apolipoprotein C-II; D053305:Apolipoprotein C-III; D001053:Apolipoproteins / Q000097:blood; D001056:Apolipoproteins C; D001629:Bezafibrate; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL; D002986:Clinical Trials as Topic; D002995:Clofibric Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D011345:Fenofibrate / Q000031:analogs & derivatives; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000378:metabolism / Q000627:therapeutic use; D008066:Lipolysis / Q000187:drug effects; D008075:Lipoproteins, HDL / Q000097:blood*; D009525:Niacin; D051381:Rats; D013329:Structure-Activity Relationship
D053304:Apolipoprotein C-II; D053305:Apolipoprotein C-III; D001053:Apolipoproteins; D001056:Apolipoproteins C; D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; C009746:etofibrate; D009525:Niacin; D002995:Clofibric Acid; D002784:Cholesterol; C006012:fenofibric acid; D011345:Fenofibrate; D001629:Bezafibrate